398HC, Scientist, Molecular Engineering

Job Code 398HC


Fate Therapeutics is currently seeking a talented and highly motivated molecular biologist with strong genetic engineering background to join a multidisciplinary R&D team for developing stem cell derived off-the-shelf immunotherapies. The candidate will be responsible for the design, engineering, and optimization of multiple genetically modified cell types including induced pluripotent stem cell (iPSC) lines used for derivation of cell therapy products. The candidate will also be involved in developing and validating novel engineering modalities to support Fate’s fast-growing preclinical pipeline. The successful candidate must demonstrate broad and in-depth knowledge of cutting-edge synthetic biology and genomic engineering techniques as well as strong expertise in generation and characterization of genetically modified cell lines. The position will require innovative thinking, strong independent and collaborative research abilities, and excellent oral and written communication skills. This is a full-time hands-on research position and is located at Fate’s corporate headquarters in San Diego, CA.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 398HC.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.